Owlet's Subscription Pivot Meets an Amazon Deadline: Tariff Refunds and a Platform Story

FDA clearance becomes a durable moat as Owlet leans into subscriptions, Web Pay, and telehealth — but a cautious guide tempers the excitement.

OWLT · Earnings Call · 2026-08-11

Owlet's Q2 2026 report was a record-breaker on multiple fronts—revenue up 29.9% to $33.9M, subscription revenue at $3.2M (+$2.4M y/y), and adjusted EBITDA of $6.7M including the tariff refund. But the real story is that management used the quarter to lay out a clearer path toward a subscription-driven platform, even as it struck a cautious tone on the second half. “Every day, Owlet is evolving more and more into a data and services platform for the earliest years of a child's life.” — Kurt Workman, President, CEO and Co-Founder · 2026-08-11

The Tariff Refund: A One-Time Lift With Real Consequences

The financial highlight is the tariff refund. Following the Supreme Court's February ruling invalidating IEEPA tariffs, Owlet received ~$4M in refunds, with $3.5M recognized in COGS. That boosted gross margin to 64.4% for Q2—yet even stripping that out, gross margin hit 54%, a 270bps improvement y/y. The company's underlying margin trajectory is clearly positive, and CFO Amanda Crawford noted the new $25M asset-based revolving facility with Wells Fargo cuts interest costs by at least 525 basis points. Management raised full-year gross margin guidance to 53%–55% and adjusted EBITDA to $10.75M–$12.75M, but reaffirmed revenue at $118M–$122M, citing an intentionally measured view.

Amazon's Deadline Becomes a Moat

The more strategically significant development didn't show up on the income statement—it came in June when Amazon notified baby-monitor sellers that products measuring vital signs without FDA clearance would be deactivated from its platform on August 10. Owlet, with its FDA-cleared Dream Sock, needed no action.

To our knowledge, no other baby monitor on the market today has secured the same clearance. If Amazon continues to enforce this requirement, we believe it could provide a longer-term competitive benefit for Owlet as any company wishing to measure and monitor vital signs would need to go through the same rigor we underwent to secure FDA clearance in order to sell on Amazon's platform.
Kurt Workman, President, CEO and Co-Founder · 2026-08-11

In the short term, however, the enforcement triggered aggressive discounting by competitors trying to clear inventory before the deadline. That hurt Owlet's Prime Day units, down 8% y/y, even as the company retained the #1 spot in baby monitoring and baby safety. This is a classic "pain today, moat tomorrow" setup—the question is how quickly the competitive field thins.

Subscription Economics: The Next Act

Beyond the tariff and Amazon story, the most important narrative is the platform shift. Owlet ended Q2 with 130,000 paying subscribers, up meaningfully, and subscription revenue grew to $3.2M. “Subscription revenue grew to a record $3.2 million, up $2.4 million year-over-year as our Owlet360 base continued to expand.” — Amanda Crawford, CFO · 2026-08-11 The company is now testing Web Pay, moving subscription billing away from the App Store's ~30% fee, which CFO Amanda Crawford said could "be significant to the margin" over time. Management is also rolling out upfront subscription at the point of purchase, with Babylist as a key partner. The lifetime value math is what founder Kurt Workman keeps coming back to: “We're now seeing nearly 30% of new users in the trial period elect the annual plan, which is really exciting for us from an LTV perspective.” — Kurt Workman, President, CEO and Co-Founder · 2026-08-11 That's a meaningful sign for retention and the path toward the 1-million-subscriber base management has set as the long-term goal. “And we think AI is going to unlock massive growth here over the next few years.” — Kurt Workman, President, CEO and Co-Founder · 2026-05-08 Meanwhile, telehealth remains a deliberate test-and-learn. Owlet OnCall is expanding access from ~5% of users to a "more seamless and proactive" experience, and management explicitly framed it as a meaningful revenue stream for next year, not this one. The international story is equally compelling: Q2 international revenue grew 214% y/y to $5.7M, and management's prior emphasis on Europe continues to pay off. “We continue to see very strong sell-through success across our European markets and continue to grow.” — Jonathan Harris, President and CEO · 2026-03-05 All told, Owlet is executing on its stated priorities with visible results. The tariff refund is a one-time boost, but the margin expansion, lower cost of capital, and the platform's subscription-attach momentum provide a more durable foundation. The Amazon enforcement could reshape the competitive landscape in Owlet's favor, though the near-term Prime Day softness is a reminder that the transition won't be linear. For a small-cap medical device company pivoting to a data-and-services model, the evidence so far suggests the strategy is working—even as management keeps guidance grounded in reality.